CCR2
Basic information
Region (hg38): 3:46353864-46360940
Previous symbols: [ "CMKBR2" ]
Links
Phenotypes
GenCC
Source:
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Polycystic lung disease | AR | Allergy/Immunology/Infectious; Pulmonary | Individuals are at increased risk of recurrent respiratory infections, and have been reported to have adverse reactions to BCG, and awareness may allow early medical management related to pulmonary health as well as vaccine regimens | Allergy/Immunology/Infectious; Pulmonary | 38157855 |
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the CCR2 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 7 | |||||
missense | 15 | 18 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 0 | |||||
Total | 0 | 0 | 15 | 5 | 5 |
Variants in CCR2
This is a list of pathogenic ClinVar variants found in the CCR2 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
3-46357586-T-TAC | Cystic disease of lung | Pathogenic (Mar 12, 2024) | ||
3-46357599-T-A | not specified | Uncertain significance (Feb 28, 2023) | ||
3-46357602-T-A | not specified | Uncertain significance (May 23, 2023) | ||
3-46357669-C-T | not specified | Uncertain significance (Nov 17, 2022) | ||
3-46357683-G-T | Benign (Jul 31, 2018) | |||
3-46357687-A-C | not specified | Uncertain significance (Aug 20, 2024) | ||
3-46357709-T-G | Cystic disease of lung | Pathogenic (Mar 12, 2024) | ||
3-46357716-C-T | Likely benign (Jul 17, 2018) | |||
3-46357717-G-A | Susceptibility to HIV infection • CCR2-related disorder | Benign; protective (Oct 18, 2019) | ||
3-46357883-T-G | Cystic disease of lung | Pathogenic (Mar 12, 2024) | ||
3-46357894-G-A | not specified | Uncertain significance (Nov 11, 2024) | ||
3-46357905-C-T | Likely benign (Dec 11, 2017) | |||
3-46357924-C-T | not specified | Uncertain significance (Jun 28, 2022) | ||
3-46357997-G-A | not specified | Uncertain significance (Oct 17, 2023) | ||
3-46358075-A-G | not specified | Uncertain significance (May 01, 2024) | ||
3-46358089-T-C | not specified | Uncertain significance (Oct 01, 2024) | ||
3-46358114-G-A | not specified | Uncertain significance (Feb 27, 2024) | ||
3-46358142-G-A | not specified | Uncertain significance (Sep 01, 2021) | ||
3-46358155-G-A | not specified | Uncertain significance (Mar 20, 2023) | ||
3-46358163-CCTGCCG-C | Cystic disease of lung | Pathogenic (Mar 12, 2024) | ||
3-46358175-C-T | CCR2-related disorder | Likely benign (May 08, 2019) | ||
3-46358182-G-A | not specified | Likely benign (Apr 13, 2022) | ||
3-46358215-C-T | not specified | Uncertain significance (Mar 12, 2024) | ||
3-46358219-G-T | not specified | Uncertain significance (Oct 01, 2024) | ||
3-46358307-T-C | CCR2-related disorder | Benign (Oct 17, 2019) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
CCR2 | protein_coding | protein_coding | ENST00000292301 | 2 | 7195 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.0234 | 0.919 | 125727 | 0 | 11 | 125738 | 0.0000437 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.0339 | 195 | 196 | 0.993 | 0.0000111 | 2443 |
Missense in Polyphen | 44 | 51.845 | 0.84868 | 719 | ||
Synonymous | -0.384 | 86 | 81.6 | 1.05 | 0.00000527 | 779 |
Loss of Function | 1.63 | 4 | 9.37 | 0.427 | 5.75e-7 | 104 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.0000289 | 0.0000289 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.0000462 | 0.0000462 |
European (Non-Finnish) | 0.0000708 | 0.0000703 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.00 | 0.00 |
Other | 0.000163 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: Receptor for the CCL2, CCL7 and CCL13 chemokines (PubMed:23408426). Receptor for the beta-defensin DEFB106A/DEFB106B (PubMed:23938203). Transduces a signal by increasing intracellular calcium ion levels (By similarity). Upon CCL2 ligation, mediates chemotaxis and migration induction through the activation of the PI3K cascade, the small G protein Rac and lamellipodium protrusion (Probable). {ECO:0000250|UniProtKB:P51683, ECO:0000269|PubMed:23408426, ECO:0000269|PubMed:23938203, ECO:0000305|PubMed:15995708}.;
- Pathway
- Chemokine signaling pathway - Homo sapiens (human);Cytokine-cytokine receptor interaction - Homo sapiens (human);Peptide GPCRs;Spinal Cord Injury;Lung fibrosis;Chemokine signaling pathway;Interleukin-10 signaling;GPCRs, Class A Rhodopsin-like;Signaling by GPCR;Signal Transduction;Antimicrobial peptides;Innate Immune System;Immune System;Chemokine receptors bind chemokines;Peptide ligand-binding receptors;Beta defensins;Class A/1 (Rhodopsin-like receptors);Defensins;GPCR ligand binding;G alpha (i) signalling events;GPCR downstream signalling
(Consensus)
Intolerance Scores
- loftool
- 0.390
- rvis_EVS
- -0.09
- rvis_percentile_EVS
- 46.92
Haploinsufficiency Scores
- pHI
- 0.182
- hipred
- N
- hipred_score
- 0.219
- ghis
- 0.494
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.121
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Ccr2
- Phenotype
- homeostasis/metabolism phenotype; cellular phenotype; growth/size/body region phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); liver/biliary system phenotype; respiratory system phenotype; immune system phenotype; skeleton phenotype; renal/urinary system phenotype; digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); vision/eye phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); pigmentation phenotype; neoplasm;
Gene ontology
- Biological process
- blood vessel remodeling;dendritic cell chemotaxis;monocyte chemotaxis;positive regulation of T-helper 1 type immune response;negative regulation of type 2 immune response;cellular calcium ion homeostasis;chemotaxis;inflammatory response;immune response;humoral immune response;cellular defense response;G protein-coupled receptor signaling pathway;negative regulation of adenylate cyclase activity;positive regulation of cytosolic calcium ion concentration;JAK-STAT cascade;response to wounding;regulation of vascular endothelial growth factor production;positive regulation of T cell chemotaxis;viral process;negative regulation of angiogenesis;cytokine-mediated signaling pathway;sensory perception of pain;calcium-mediated signaling;cellular homeostasis;hemopoiesis;positive regulation of interferon-gamma production;positive regulation of interleukin-2 production;T-helper 17 cell chemotaxis;positive regulation of tumor necrosis factor biosynthetic process;negative regulation of eosinophil degranulation;positive regulation of alpha-beta T cell proliferation;homeostasis of number of cells within a tissue;positive regulation of inflammatory response;positive regulation of T cell activation;cell chemotaxis;leukocyte adhesion to vascular endothelial cell;chemokine-mediated signaling pathway;positive regulation of monocyte chemotaxis;positive regulation of immune complex clearance by monocytes and macrophages;neutrophil clearance;positive regulation of cold-induced thermogenesis;positive regulation of leukocyte tethering or rolling;positive regulation of monocyte extravasation;positive regulation of CD8-positive, alpha-beta T cell extravasation;positive regulation of astrocyte chemotaxis;positive regulation of hematopoietic stem cell migration
- Cellular component
- cytoplasm;cytosol;plasma membrane;integral component of plasma membrane;external side of plasma membrane;integral component of membrane;dendrite;neuronal cell body;perikaryon;perinuclear region of cytoplasm
- Molecular function
- chemokine receptor activity;protein binding;C-C chemokine receptor activity;chemokine binding;C-C chemokine binding;CCR2 chemokine receptor binding;chemokine (C-C motif) ligand 2 binding;chemokine (C-C motif) ligand 12 binding;chemokine (C-C motif) ligand 7 binding;protein homodimerization activity